Abstract

Melanoma is one of the most aggressive and lethal cancers worldwide. Despite recent progress in melanoma therapy, the prognosis for metastasized melanoma continues to be poor. Xanthohumol (XN), a prenylated chalcone derived from hop cones, is known to possess a broad spectrum of chemopreventive and anticancer activities. However, few studies have analyzed functional XN effects on melanoma cells and there have been no previous in vivo studies of its effects on metastasis. The aim of this study was to investigate the impact of XN on the tumorigenic and liver metastatic activity of melanoma cells. XN exhibited dose-dependent cytotoxic effects on human melanoma cell lines (Mel Ju; Mel Im) in vitro. Functional analysis in the subtoxic dose-range revealed that XN dose-dependently inhibited proliferation, colony formation, and migratory activity of melanoma cells. Subtoxic XN doses also induced markers of endoplasmic reticulum stress but inhibited the phosphorylation of the protumorigenic c-Jun N-terminal kinases (JNK). Furthermore, XN effects on hepatic metastasis were analyzed in a syngeneic murine model (splenic injection of murine B16 melanoma cells in C57/BL6 mice). Here, XN significantly reduced the formation of hepatic metastasis. Metastases formed in the liver of XN-treated mice revealed significantly larger areas of central necrosis and lower Ki67 expression scores compared to that of control mice. In conclusion, XN inhibits tumorigenicity of melanoma cells in vitro and significantly reduced hepatic metastasis of melanoma cells in mice. These data, in conjunction with an excellent safety profile that has been confirmed in previous studies, indicate XN as a promising novel agent for the treatment of hepatic (melanoma) metastasis.

MeSH

Growth, Melanoma, Neoplasm Metastasis, Cells, Therapeutics, Liver, Chalcone

Cited by

• A Novel Look at Mechanisms and Applications of Xanthohumol (XN) in Dermatology and Cosmetology. Int J Mol Sci, 2024
• The Challenging Melanoma Landscape: From Early Drug Discovery to Clinical Approval. Cells, 2021
• Advances in Immunosuppressive Agents Based on Signal Pathway. Front Pharmacol, 2022
• Ligand and Structure-Based Virtual Screening in Combination, to Evaluate Small Organic Molecules as Inhibitors for the XIAP Anti-Apoptotic Protein: The Xanthohumol Hypothesis. Molecules, 2022
• Exploring the inhibitory potential of xanthohumol on MEK1/2: a molecular docking and dynamics simulation investigation. Res Pharm Sci, 2025
• Two Important Anticancer Mechanisms of Natural and Synthetic Chalcones. Int J Mol Sci, 2022
• Differential Inhibite Effect of Xanthohumol on HepG2 Cells and Primary Hepatocytes. Dose Response, 2022
• Xanthohumol modulate autophagy and ER stress to counteract stemness and enhance cisplatin efficacy in head and neck squamous cell carcinoma. Sci Rep, 2025
• Xanthohumol for Human Malignancies: Chemistry, Pharmacokinetics and Molecular Targets. Int J Mol Sci, 2021
• A Novel Tri-Hydroxy-Methylated Chalcone Isolated from with Anti-Cancer Potential Targeting Pro-Survival Proteins. Int J Mol Sci, 2023
• A comprehensive review of the benefits of drinking craft beer: Role of phenolic content in health and possible potential of the alcoholic fraction. Curr Res Food Sci, 2023
• Synthesis of -Chalcones Based on Green Chemistry Strategies and Their Cytotoxicity Toward Human MeWo and A375 Melanoma Cell Lines. Molecules, 2024
• Chalcone-Acridine Hybrid Suppresses Melanoma Cell Progression via G2/M Cell Cycle Arrest, DNA Damage, Apoptosis, and Modulation of MAP Kinases Activity. Int J Mol Sci, 2022
• Analytical Quality by Design Driven Development and Validation of UV-Visible Spectrophotometric Method for Quantification of Xanthohumol in Bulk and Solid Lipid Nanoparticles. Turk J Pharm Sci, 2023